Effectiveness of infliximab after adalimumab failure in Crohn's disease

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 37

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

339

HTML

1696

Tables (1-2)

145

Sum=2180

Oct 7, 2012 (publication date) through Aug 28, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Article

World J Gastroenterol. Oct 7, 2012; 18(37): 5219-5224
Published online Oct 7, 2012. doi: 10.3748/wjg.v18.i37.5219

Table 1 Characteristics of study patients n (%)

Gender (female %)	10 (67)
Median age (yr)	33
Time of evolution to adalimumab therapy (mo)	69
Location
L1	7 (47)
L2	1 (6)
L3	7 (47)
Behavior (%)
Inflammatory	10 (67)
Stricturing	4 (27)
Fistulizing	1 (6)
Perianal disease	4 (27)
Smoking habit	3 (21)
Previous surgical resection	7 (47)
Concomitant immunosuppressants	11 (71)
Reason for discontinuation of adalimumab
Partial response	7 (47)
Loss of efficacy	5 (33)
Adverse events	3 (20)

L1: Ileum; L2: Colon; L3: Ileum and colon.

Citation: Chaparro M, Andreu M, Barreiro-de Acosta M, García-Planella E, Ricart E, Domènech E, Esteve M, Merino O, Nos P, Peñalva M, Gisbert JP. Effectiveness of infliximab after adalimumab failure in Crohn's disease. World J Gastroenterol 2012; 18(37): 5219-5224
URL: https://www.wjgnet.com/1007-9327/full/v18/i37/5219.htm
DOI: https://dx.doi.org/10.3748/wjg.v18.i37.5219